Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.

Knorr DA, Ravetch JV.

Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.

PMID:
30397179
2.

Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.

Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12023-12027. doi: 10.1073/pnas.1812833115. Epub 2018 Nov 5.

3.

IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.

Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10915-E10924. doi: 10.1073/pnas.1811615115. Epub 2018 Oct 29.

4.

Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.

Knorr DA, Dahan R, Ravetch JV.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11048-11053. doi: 10.1073/pnas.1810566115. Epub 2018 Oct 8.

5.

Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Wang TT, Bournazos S, Ravetch JV.

Curr Opin Immunol. 2018 Aug;53:124-129. doi: 10.1016/j.coi.2018.04.026. Epub 2018 May 10. Review.

6.

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA.

Leukemia. 2018 Feb;32(2):547-549. doi: 10.1038/leu.2017.293. Epub 2017 Sep 19. No abstract available.

7.

Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.

Maamary J, Wang TT, Tan GS, Palese P, Ravetch JV.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10172-10177. doi: 10.1073/pnas.1707950114. Epub 2017 Sep 5.

8.

Fcγ Receptor Function and the Design of Vaccination Strategies.

Bournazos S, Ravetch JV.

Immunity. 2017 Aug 15;47(2):224-233. doi: 10.1016/j.immuni.2017.07.009. Review.

9.

Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.

Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, Ravetch JV, Wittrup KD.

J Mol Biol. 2017 Aug 4;429(16):2528-2541. doi: 10.1016/j.jmb.2017.07.001. Epub 2017 Jul 8.

10.

Diversification of IgG effector functions.

Bournazos S, Ravetch JV.

Int Immunol. 2017 Jul 1;29(7):303-310. doi: 10.1093/intimm/dxx025. Review.

11.

Signaling by Antibodies: Recent Progress.

Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV.

Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433. Review.

12.

Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis.

Raz A, Serrano A, Lawson C, Thaker M, Alston T, Bournazos S, Ravetch JV, Fischetti VA.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4781-4786. doi: 10.1073/pnas.1619249114. Epub 2017 Apr 20.

13.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

14.

DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo.

Lehmann CHK, Baranska A, Heidkamp GF, Heger L, Neubert K, Lühr JJ, Hoffmann A, Reimer KC, Brückner C, Beck S, Seeling M, Kießling M, Soulat D, Krug AB, Ravetch JV, Leusen JHW, Nimmerjahn F, Dudziak D.

J Exp Med. 2017 May 1;214(5):1509-1528. doi: 10.1084/jem.20160951. Epub 2017 Apr 7.

15.

Modulating IgG effector function by Fc glycan engineering.

Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490. doi: 10.1073/pnas.1702173114. Epub 2017 Mar 13.

16.

Attenuated Vaccines for Augmented Immunity.

Bournazos S, Ravetch JV.

Cell Host Microbe. 2017 Mar 8;21(3):314-315. doi: 10.1016/j.chom.2017.02.016.

17.

Anti-retroviral antibody FcγR-mediated effector functions.

Bournazos S, Ravetch JV.

Immunol Rev. 2017 Jan;275(1):285-295. doi: 10.1111/imr.12482. Review.

PMID:
28133801
18.

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.

Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV.

Science. 2017 Jan 27;355(6323):395-398. doi: 10.1126/science.aai8128.

19.

The Role and Function of Fcγ Receptors on Myeloid Cells.

Bournazos S, Wang TT, Ravetch JV.

Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.MCHD-0045-2016. Review.

20.

Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement.

Dahan R, Ravetch JV.

Cancer Cell. 2016 Sep 12;30(3):369-371. doi: 10.1016/j.ccell.2016.08.007.

21.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2016 Jun 16;165(7):1609-1620. doi: 10.1016/j.cell.2016.04.050.

22.

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV.

Cancer Cell. 2016 Jun 13;29(6):820-831. doi: 10.1016/j.ccell.2016.05.001. Epub 2016 Jun 2.

23.

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.

Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C, Li F, Ravetch JV, Karlsson MC.

Cell Rep. 2016 May 31;15(9):2000-11. doi: 10.1016/j.celrep.2016.04.084. Epub 2016 May 19.

24.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC.

Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.

25.

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

DiLillo DJ, Palese P, Wilson PC, Ravetch JV.

J Clin Invest. 2016 Feb;126(2):605-10. doi: 10.1172/JCI84428. Epub 2016 Jan 5.

26.

Fcγ receptor pathways during active and passive immunization.

Bournazos S, Ravetch JV.

Immunol Rev. 2015 Nov;268(1):88-103. doi: 10.1111/imr.12343. Review.

PMID:
26497515
27.

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV.

Cancer Cell. 2015 Oct 12;28(4):543. doi: 10.1016/j.ccell.2015.09.011. Epub 2015 Oct 12. No abstract available.

28.

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV.

Cancer Cell. 2015 Sep 14;28(3):285-95. doi: 10.1016/j.ccell.2015.08.004. Erratum in: Cancer Cell. 2015 Oct 12;28(4):543.

29.

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization.

Bournazos S, DiLillo DJ, Ravetch JV.

J Exp Med. 2015 Aug 24;212(9):1361-9. doi: 10.1084/jem.20151267. Epub 2015 Aug 17. Review.

30.

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.

Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV.

Cell. 2015 Jul 2;162(1):160-9. doi: 10.1016/j.cell.2015.06.026.

31.

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.

DiLillo DJ, Ravetch JV.

Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120. Review.

32.

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

DiLillo DJ, Ravetch JV.

Cell. 2015 May 21;161(5):1035-1045. doi: 10.1016/j.cell.2015.04.016. Epub 2015 May 11.

33.

Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Fiebiger BM, Maamary J, Pincetic A, Ravetch JV.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2385-94. doi: 10.1073/pnas.1505292112. Epub 2015 Apr 13.

34.

Immune complexes: not just an innocent bystander in chronic viral infection.

Wang TT, Ravetch JV.

Immunity. 2015 Feb 17;42(2):213-215. doi: 10.1016/j.immuni.2015.01.022.

35.

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2014 Sep 11;158(6):1243-1253. doi: 10.1016/j.cell.2014.08.023.

36.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

37.

humanized mice to study FcγR function.

Bournazos S, DiLillo DJ, Ravetch JV.

Curr Top Microbiol Immunol. 2014;382:237-48. doi: 10.1007/978-3-319-07911-0_11.

PMID:
25116103
38.

Type I and type II Fc receptors regulate innate and adaptive immunity.

Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV.

Nat Immunol. 2014 Aug;15(8):707-16. doi: 10.1038/ni.2939. Review.

PMID:
25045879
39.

Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.

Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ.

J Mol Biol. 2014 Sep 9;426(18):3166-3179. doi: 10.1016/j.jmb.2014.07.006. Epub 2014 Jul 15.

40.

Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms.

Li F, Smith P, Ravetch JV.

J Immunol. 2014 Apr 1;192(7):3021-8. doi: 10.4049/jimmunol.1302934. Epub 2014 Feb 21.

41.

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

DiLillo DJ, Tan GS, Palese P, Ravetch JV.

Nat Med. 2014 Feb;20(2):143-51. doi: 10.1038/nm.3443. Epub 2014 Jan 12.

42.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV.

J Clin Invest. 2014 Feb;124(2):725-9. doi: 10.1172/JCI72676. Epub 2014 Jan 9.

43.

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.

Li F, Ravetch JV.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6. doi: 10.1073/pnas.1319502110. Epub 2013 Nov 11.

44.

Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc.

Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3547. No abstract available.

45.

Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling.

Wermeling F, Anthony RM, Brombacher F, Ravetch JV.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13487-91. doi: 10.1073/pnas.1312525110. Epub 2013 Jul 29.

46.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA.

J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.

47.

Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J.

J Virol. 2013 Aug;87(15):8535-44. doi: 10.1128/JVI.00868-13. Epub 2013 May 29.

48.

General mechanism for modulating immunoglobulin effector function.

Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9868-72. doi: 10.1073/pnas.1307864110. Epub 2013 May 22.

49.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Nature. 2012 Dec 6;492(7427):118-22. doi: 10.1038/nature11604. Epub 2012 Oct 24.

50.

A mouse model for HIV-1 entry.

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15859-64. Epub 2012 Sep 10.

Supplemental Content

Loading ...
Support Center